Loading...
•
Sep 30, 2025
•/
Ascendis Pharma Q3 2025 Earnings Report
Ascendis Pharma reported a Q3 2025 net loss of €61 million despite strong revenue growth driven by YORVIPATH and SKYTROFA.
Key Takeaways
Ascendis Pharma delivered strong top-line growth in Q3 2025 with total revenue of €213.6 million, largely driven by commercial success of YORVIPATH and SKYTROFA. However, despite an operating profit of €11 million, the company posted a net loss due to substantial finance expenses.
Achieved total revenue of €213.6 million, a significant increase from €57.8 million in Q3 2024.
YORVIPATH generated €143.1 million in revenue and SKYTROFA €50.7 million.
Reported operating income of €11 million but a net loss of €61 million due to €66.9 million in finance expenses.
Cash position rose to €539 million as of September 30, 2025, up €45 million from Q2 2025.
Revenue by Segment
Forward Guidance
Ascendis anticipates continued momentum from YORVIPATH and SKYTROFA, while preparing for potential approval of TransCon CNP. Strategic clinical and regulatory milestones remain key focus areas.
Positive Outlook
- YORVIPATH is now available in over 30 countries and launched in Japan.
- FDA approval of SKYTROFA label expansion into adult GHD.
- TransCon CNP under FDA Priority Review with November 30 PDUFA date.
- Increased patient and provider adoption for YORVIPATH in the U.S.
- Planned launch of TransCon CNP + hGH Phase 3 trial in Q4 2025.
Challenges Ahead
- Q3 2025 resulted in a €61 million net loss despite operational profitability.
- €66.9 million in finance expenses largely due to remeasurement losses.
- SG&A expenses surged to €113.4 million due to global expansion costs.
- Ongoing R&D costs remain high at €66.9 million for the quarter.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...